Please assess the completion status of the following clinical trial:

Trial Title: Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inborn and outborn infants of 29 0/7 to 33 6/7 weeks gestational age at birth~* admitted to hospitals of the NICHD NRN who, are at time of enrollment:~* ≤35 6/7 weeks post-menstrual age at the time of randomization~* Receiving caffeine with plan to discontinue treatment or just discontinued caffeine treatment~* Receiving feeds at a volume of ≥120 ml/kg/day by oral and/or tube feeding~* Ability to start study medication within 72 hours after stopping caffeine~Exclusion Criteria:~* On respiratory therapy (oxygen more than room air equivalent for high altitude sites, nasal cannula, continuous positive pressure ventilation, and/or mechanical ventilation)~* Infants who would otherwise be discharged home on apnea monitor due to underlying disease or family history, including history of a sibling with sudden infant death syndrome~* Parental request for apnea monitor~* Congenital heart disease other than atrial septal defect, ventricular septal defect, or patent ductus arteriosus~* Neuromuscular conditions affecting respiration~* Major congenital malformation and/or genetic disorder~* Plans to transfer to a non-NRN site before discharge~* Unable to obtain parental or guardian consent

- Gender: ALL
- Minimum Age: 29 Weeks
- Maximum Age: 33 Weeks
- Healthy Volunteers: f

Study Arms:
- Caffeine Citrate (Type: EXPERIMENTAL): Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).